IP Library Granted Patent US 8,907,091
Granted Patent B2
US 8,907,091 · App. 12/231,297 · Granted Dec 9, 2014

Processes and intermediates for preparing fused heterocyclic kinase inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,907,091
App. No.
12/231,297
Granted
Dec 9, 2014
Kind
B2
Abstract

This invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.

Claims (28)

1. A process for preparing a compound of Formula (A):

and pharmaceutically acceptable salts thereof,

wherein

D is pyridine optionally substituted with 1 to 5 independently selected R 38 ;

M is

Z is —O—;

Ar is phenyl; and

G is

wherein

each R 38 is independently selected from —(CH 2 ) j NR 39 (CH 2 ) n R 36 and —(CH 2 ) n NR 36 R 39 , wherein each j is an integer independently ranging from 0 to 4 and n is an integer ranging from 0 to 6;

R 36 is selected from the group consisting of H, —OH, C 1 -C 6 alkyl, —(CH 2 ) n O(CH 2 ) i OR 37 , —(CH 2 ) n CN(CH 2 ) n OR 37 , —(CH 2 ) n CN(CH 2 ) n R 37 , and —(CH 2 ) n OR 37 , wherein each n is an integer independently ranging from 0 to 6 and i is an integer ranging from 2 to 6;

R 37 is selected from H, —O—C 1 -C 6 alkyl, and optionally substituted C 1 -C 6 alkyl;

R 39 is selected from the group consisting of H and C 1 -C 6 alkyl;

R 13 is —H,

Q is phenyl optionally substituted with between zero and four halogens;

R 11 and R 12 are H

the process comprising

reacting a compound represented by the Formula (A-1)

wherein

PG is a R 38 substituent protected with a protecting group; and

RG 1 is —NH 2 ; with a compound represented by the Formula (A-2):

RG 2 -G 1   (A-2),

wherein RG 2 G 1 is

wherein the reaction is performed at 70° C. in a mixture of isopropanol and acetonitrile, such that the reaction of —RG 1 with RG 2 -G 1 forms

and removing the protecting group.

2. The process according to claim 1 , wherein G is selected from the group consisting of

3. The process according to claim 1 , wherein D is substituted with one R 38 , wherein R 38 is —(CH 2 ) j NR 39 (CH 2 ) n R 36 , wherein j is an integer from 0 to 4, n is an integer from 0 to 6, R 39 is H or C 1 -C 6 alkyl, and R 36 is —(CH 2 ) n OR 37 , wherein n is an integer ranging from 0 to 6, and R 37 is H or C 1 -C 6 alkyl.

4. The process according to claim 1 wherein RG 2 -G 1 is

Assignments (6)
CHANGE OF NAME Recorded Oct 19, 2022
From: METHYLGENE INC.
To: METHYLGENE ULC
Reel/Frame 061470/0462 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2022
From: METHYLGENE ULC
To: MIRATI THERAPEUTICS, INC.
Reel/Frame 061470/0650 →
CHANGE OF NAME Recorded Oct 27, 2010
From: METHYLGENE, INC.
To: 92229129 QUEBEC INC.
Reel/Frame 025200/0827 →
MERGER Recorded Oct 27, 2010
From: 7503547 CANADA INC.
To: METHYLGENE, INC.
Reel/Frame 025201/0647 →
CHANGE OF NAME Recorded Oct 19, 2010
From: 922209129 QUEBEC INC., (FORMERLY "METHYLGENE, INC.")
To: 7503547 CANADA, INC.
Reel/Frame 025159/0476 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2008
From: RAEPPEL, FRANCK; ISAKOVIC, LJUBOMIR; CLARIDGE, STEPHEN WILLIAM; MANNION, MICHAEL; ZHAN, LIJIE; GRANGER, MARIE-CLAUDE; VAISBURG, ARKADII; NANTEL, MIGUEL
To: METHYLGENE INC.
Reel/Frame 021752/0109 →